AEON Biopharma appoints Robert Bancroft as CEO effective April 29; Jost Fisher remains chairman

AEON Biopharma, Inc.

Bancroft appointed PEO, President, CEO and Class I director effective April 29, 2025.
Jost Fisher steps down as Interim CEO but continues as chairman and on audit/comp committees.
Bancroft base salary $425k, eligible for annual bonus target 50% of salary.
Bancroft receives 59,034 stock options and 177,103 RSUs under new Inducement Plan (1M shares reserved).
Prior role: GM of Therapeutics at Revance Therapeutics until its acquisition by Crown Labs in Feb 2024.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Jost Fisher

Interim President and Chief Executive Officer

AEON · AEON Biopharma, Inc.

Effective: 2025-04-29
Successor: Robert Bancroft
Filed: April 21, 2025, 7:59 PM ET

Jost Fisher will step down as Interim President and Chief Executive Officer but will continue to serve as chairman of the Board, a member of the audit committee and chair of the compensation committee.

Appointed

Robert Bancroft

Chief Executive Officer, President and Principal Executive Officer

AEON · AEON Biopharma, Inc.

Effective: 2025-04-29
Filed: April 21, 2025, 7:59 PM ET

On April 19, 2025, the board of directors (the “Board”) of AEON BioPharma, Inc. (the “Company”) appointed Robert Bancroft, age 60, as the Company’s Principal Executive Officer, President, Chief Executive Officer and member of the Board to serve as a Class I director, effective as of April 29, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jost Fisher changed role as Interim President and Chief Executive Officer at AEON Biopharma, Inc..

Action: stepped down as Interim President and Chief Executive Officer
Role: Interim President and Chief Executive Officer

Exact text from the filing

Jost Fisher will step down as Interim President and Chief Executive Officer but will continue to serve as chairman of the Board, a member of the audit committee and chair of the compensation committee.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Bancroft was appointed as Chief Executive Officer, President and Principal Executive Officer at AEON Biopharma, Inc..

Action: appointed
Role: Chief Executive Officer, President and Principal Executive Officer

Exact text from the filing

On April 19, 2025, the board of directors (the “Board”) of AEON BioPharma, Inc. (the “Company”) appointed Robert Bancroft, age 60, as the Company’s Principal Executive Officer, President, Chief Executive Officer and member of the Board to serve as a Class I director, effective as of April 29, 2025.

View on SEC.gov

AEON Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001837607-25-000030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.